Company insiders
Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source | Follow |
|---|---|---|---|---|---|---|---|
| SHUGAR DANIEL S Chief Executive Officer · Director · Nextpower Inc. | NXT Nextpower Inc. | Exercise or conversionFiling detailsSEC transaction code M Stock Option (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 119268 · The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 19, 2026. | 2026-11-18 | 2026-11-20 | 34,253 shares/units | SEC 4 | Follow |
| SHUGAR DANIEL S Chief Executive Officer · Director · Nextpower Inc. | NXT Nextpower Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 871131 · SEC code covers open-market or private transactions · The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 19, 2026. · The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $80.00 to $80.38, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission (SEC), upon request, full information regarding the number of shares sold at each separate price within such ranges. | 2026-11-19 | 2026-11-20 | ≈ $36,046.22 450 shares/units | SEC 4 | Follow |
| SHUGAR DANIEL S Chief Executive Officer · Director · Nextpower Inc. | NXT Nextpower Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 871581 · The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 19, 2026. | 2026-11-19 | 2026-11-20 | 450 shares/units | SEC 4 | Follow |
| SHUGAR DANIEL S Chief Executive Officer · Director · Nextpower Inc. | NXT Nextpower Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 871131 · SEC code covers open-market or private transactions · The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 19, 2026. · The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $81.059 to $81.357, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission (SEC), upon request, full information regarding the number of shares sold at each separate price within such ranges. | 2026-11-18 | 2026-11-20 | ≈ $123,391.26 1,519 shares/units | SEC 4 | Follow |
| SHUGAR DANIEL S Chief Executive Officer · Director · Nextpower Inc. | NXT Nextpower Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 872650 · SEC code covers open-market or private transactions · The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 19, 2026. · The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $80.000 to $80.953, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission (SEC), upon request, full information regarding the number of shares sold at each separate price within such ranges. | 2026-11-18 | 2026-11-20 | ≈ $2,630,841.40 32,734 shares/units | SEC 4 | Follow |
| SHUGAR DANIEL S Chief Executive Officer · Director · Nextpower Inc. | NXT Nextpower Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 905384 · The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 19, 2026. | 2026-11-18 | 2026-11-20 | 34,253 shares/units | SEC 4 | Follow |
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | SellFiling detailsSEC transaction code S Common Stock · Indirect ownership · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. · Reported balance after transaction: 475686 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. · Represents the weighted average sale price of the shares sold from $79.04 to $79.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. · The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. | 2026-11-19 | 2026-11-20 | ≈ $118,939.50 1,500 shares/units | SEC 4 | Follow |
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | SellFiling detailsSEC transaction code S Common Stock · Indirect ownership · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. · Reported balance after transaction: 477186 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. · Represents the weighted average sale price of the shares sold from $78.00 to $78.98 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. · The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. | 2026-11-19 | 2026-11-20 | ≈ $665,977.55 8,500 shares/units | SEC 4 | Follow |
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | SellFiling detailsSEC transaction code S Common Stock · Indirect ownership · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. · Reported balance after transaction: 485686 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. · Represents the weighted average sale price of the shares sold from $77.43 to $78.23 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. · The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. | 2026-11-18 | 2026-11-20 | ≈ $678,884.05 8,723 shares/units | SEC 4 | Follow |
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | SellFiling detailsSEC transaction code S Common Stock · Indirect ownership · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. · Reported balance after transaction: 494409 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. · Represents the weighted average sale price of the shares sold from $76.43 to $77.42 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. · The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. | 2026-11-18 | 2026-11-20 | ≈ $98,318.15 1,277 shares/units | SEC 4 | Follow |
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 243327 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. · Represents the weighted average sale price of the shares sold from $77.43 to $78.23 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. | 2026-11-18 | 2026-11-20 | ≈ $2,372,948.28 30,490 shares/units | SEC 4 | Follow |
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 273817 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. · Represents the weighted average sale price of the shares sold from $76.43 to $77.42 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. | 2026-11-18 | 2026-11-20 | ≈ $345,692.28 4,490 shares/units | SEC 4 | Follow |
| Schaeffer Orlov S Nicole Chief People Strategy Officer · INSMED Inc | INSM INSMED Inc | Exercise or conversionFiling detailsSEC transaction code M Stock Option (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 0 · This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 11, 2026, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. · The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. | 2026-11-19 | 2026-11-20 | 45,700 shares/units | SEC 4 | Follow |
| Schaeffer Orlov S Nicole Chief People Strategy Officer · INSMED Inc | INSM INSMED Inc | Exercise or conversionFiling detailsSEC transaction code M Stock Option (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 0 · This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 11, 2026, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. · The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. | 2026-11-19 | 2026-11-20 | 55,400 shares/units | SEC 4 | Follow |
| Schaeffer Orlov S Nicole Chief People Strategy Officer · INSMED Inc | INSM INSMED Inc | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 41895 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 11, 2026, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. · This is the weighted average sales price representing 2,262 shares sold at prices ranging from $147.38 to $148.01 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. | 2026-11-19 | 2026-11-20 | ≈ $333,645.00 2,262 shares/units | SEC 4 | Follow |
| Schaeffer Orlov S Nicole Chief People Strategy Officer · INSMED Inc | INSM INSMED Inc | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 44157 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 11, 2026, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. · This is the weighted average sales price representing 8,539 shares sold at prices ranging from $146.10 to $147.09 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. | 2026-11-19 | 2026-11-20 | ≈ $1,253,183.64 8,539 shares/units | SEC 4 | Follow |
| Schaeffer Orlov S Nicole Chief People Strategy Officer · INSMED Inc | INSM INSMED Inc | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 52696 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 11, 2026, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. · This is the weighted average sales price representing 90,299 shares sold at prices ranging from $145.00 to $145.93 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. | 2026-11-19 | 2026-11-20 | ≈ $13,098,772.94 90,299 shares/units | SEC 4 | Follow |
| Schaeffer Orlov S Nicole Chief People Strategy Officer · INSMED Inc | INSM INSMED Inc | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 142995 · This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 11, 2026, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. | 2026-11-19 | 2026-11-20 | 45,700 shares/units | SEC 4 | Follow |
| Schaeffer Orlov S Nicole Chief People Strategy Officer · INSMED Inc | INSM INSMED Inc | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 97295 · This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 11, 2026, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. · Includes 141 shares acquired through the Company's 2018 Employee Stock Purchase Plan. | 2026-11-19 | 2026-11-20 | 55,400 shares/units | SEC 4 | Follow |
| Baes Nicholas Chief Operating Officer · Bakkt, Inc. | BKKT Bakkt, Inc. | SellFiling detailsSEC transaction code S Class A Common Stock · Direct ownership · Reported balance after transaction: 127114 · SEC code covers open-market or private transactions · The sales were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 08/19/2026. · Represents a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.64 to $2.84, inclusive. · Includes 74,330 shares of Class A Common Stock subject to restricted stock units that remain subject to vesting. | 2026-11-18 | 2026-11-20 | ≈ $19,219.75 6,989 shares/units | SEC 4 | Follow |
| Veinstein Bar President, A&G · CLARIVATE PLC | CLVT CLARIVATE PLC | SellFiling detailsSEC transaction code S Ordinary Shares · Direct ownership · Reported balance after transaction: 1008458 · SEC code covers open-market or private transactions · The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2026. · The price reported is a weighted average price. The prices ranged from $2.07 to $2.18, inclusive. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. | 2026-11-18 | 2026-11-20 | ≈ $542,208.54 254,558 shares/units | SEC 4 | Follow |
| Froetscher Janet P Director · Cboe Global Markets, Inc. | CBOE Cboe Global Markets, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 11422 · SEC code covers open-market or private transactions · The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 11, 2026. | 2026-11-18 | 2026-11-20 | ≈ $525,681.92 1,448 shares/units | SEC 4 | Follow |
| Harper Gordon CFO · Armour Residential REIT, Inc. | ARR Armour Residential REIT, Inc. | BuyFiling detailsSEC transaction code P Common Stock, par value $0.001 per share · Direct ownership · Reported balance after transaction: 36772 · SEC code covers open-market or private transactions | 2026-11-20 | 2026-11-20 | ≈ $27,247.25 2,500 shares/units | SEC 4 | Follow |
| THOMAS MICHAEL H Director · Installed Building Products, Inc. | IBP Installed Building Products, Inc. | Gift or transferFiling detailsSEC transaction code G Common Stock, $0.01 par value per share · Direct ownership · Reported balance after transaction: 7630 · Gift to a charitable organization. | 2026-11-18 | 2026-11-20 | 1,000 shares/units | SEC 4 | Follow |
| THOMAS MICHAEL H Director · Installed Building Products, Inc. | IBP Installed Building Products, Inc. | SellFiling detailsSEC transaction code S Common Stock, $0.01 par value per share · Direct ownership · Reported balance after transaction: 8630 · SEC code covers open-market or private transactions | 2026-11-18 | 2026-11-20 | ≈ $136,672.90 598 shares/units | SEC 4 | Follow |
Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.